title: Efficacy and safety of rituximab in rheumatic diseases.
abstract: B-cell depleting therapy is now in clinical use for more than 10 years in rheumatology. In 2001, a first report was published on five rheumatoid arthritis patients responding to the chimeric anti-CD20 antibody rituximab. Since then, numerous clinical trials, prospective and retrospective studies, registry data as well as case reports on the use of rituximab in autoimmune rheumatic diseases have been published. This review gives a short overview on clinical data of rituximab in rheumatic diseases currently available.
authors: Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling, 1st Medical Department, Hanusch Hospital, Heinrich-Collin-Straße 30, 1140, Vienna, Austria, eva.rath@wgkk.at.
authors: Eva
authors: E
authors: Rath
authors: Jochen
authors: J
authors: Zwerina
authors: Bastian
authors: B
authors: Oppl
authors: Valerie
authors: V
authors: Nell-Duxneuner
mesh_terms: D019268:Antibodies, Antineutrophil Cytoplasmic / Q000187:drug effects; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000276:immunology; D001688:Biological Products / Q000009:adverse effects / Q000627:therapeutic use*; D014890:Granulomatosis with Polyangiitis / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D000069283:Rituximab / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D019268:Antibodies, Antineutrophil Cytoplasmic; D018501:Antirheumatic Agents; D001688:Biological Products; D000069283:Rituximab